[29V09-am] 薬物治療（基礎）②/その他

Mon. Mar 29, 2021 10:24 AM - 11:36 AM [Room V09] Oral Presentation 9 (Online)

座長：花輪剛久（東京理大薬）、有吉範高（岡山大院医歯薬）

+Add all to schedule

10:24 AM - 10:36 AM

[29V09-am08] A novel non-covalent Keap1-Nrf2 inhibitor attenuates kidney injury in an ischemia-reperfusion model by Nrf2 activation

○Sayaka Ogi¹, Hidetoshi Sunamoto¹, Hirohiko Fukiya¹, Hayato Nishiyama¹, Futoshi Nara¹, Kazuhiro Onuma¹ (1. Pharm. Res. Lab., UBE Inds. Ltd.)

10:36 AM - 10:48 AM

[29V09-am09S] Reversible keap1 inhibitor ameliorates renal function and pathology in mouse model of alport syndrome

○Shota Kaseda^1,2, Yuya Sannomiya¹, Jun Kuwazuru¹, Sayaka Ogi³, Ryoko Sasaki¹, Hidetoshi Sunamoto³, Hirohiko Fukiya³, Hayato Nishiyama³, Misato Kamura^1,2, Saki Niinou¹, Jun Horizono¹, Yuimi Koyama¹, Mary Ann Suico¹, Kazuhiro Onuma³, Futoshi Nara³, Tsuyoshi Shuto¹, Hirofumi Kai¹ (1. Grad. Sch. Pharm Sci., Kumamoto Univ., 2. HIGO program., Kumamoto Univ., 3. Pharm. Res. Lab., UBE Inds. Ltd.)

Withdrawn

10:48 AM - 11:00 AM

[29V09-am10] [Withdrawn]

11:00 AM - 11:12 AM

[29V09-am11] Investigation of biomarkers and preventive strategy of erlotinib-induced skin rash in rats

○Iqbal Julian¹, Takuya Iwamoto^1,2 (1. Department of Clinical Pharmaceutics, Graduate School of Medicine, Mie University, 2. Department of Pharmacy, Mie University Hospital)

11:12 AM - 11:24 AM

[29V09-am12S] Indoxyl sulfate contributes to renal fibrosis via mTORC1 signaling

○Takehiro Nakano¹, Hiroshi Watanabe¹, Tadashi Imafuku¹, Motoko Tanaka², Kazutaka Matsushita², Masafumi Fukagawa³, Hitoshi Maeda¹, Toru Maruyama¹ (1. Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan, 2. Akebono Clinic, Kumamoto, Japan, 3. Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan)

11:24 AM - 11:36 AM

[29V09-am13S] Plasma Curcumin level of the novel Curcumin preparation, ASD-Cur was higher than that of the existing preparation

○Shiomi Naito¹, Yoichi Sunagawa^1,2,3, Yusuke Miyazaki¹, Masafumi Funamoto¹, Kana Shimizu¹, Satoshi Shimizu¹, Sari Nurmila¹, Yasushi Katanasaka^1,2,3, Atsushi Imaizumi⁴, Tadashi Hashimoto⁴, Koji Hasegawa³, Tatsuya Morimoto^1,2,3 (1. Sch. Pharm. Sci., Univ. of Shizuoka, 2. Shizuoka. General Hosp., 3. Kyoto Med. Ctr., NHO, 4. Therabiopharma)

Session information